NCT05856981View on ClinicalTrials.gov

Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

April 3, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Solid Tumor, AdultMetastatic Solid TumorRefractory Cancer
Interventions
DRUG

ADU-1805

anti-SIRPα monoclonal antibody

DRUG

Pembrolizumab

Keytruda

Trial Locations (9)

22205

RECRUITING

Virginia Cancer Specialists, Fairfax

28078

RECRUITING

Carolina BioOncology Institute - Cancer Research Clinic, Huntersville

44718

RECRUITING

Gabrail Cancer & Research Center, Canton

48202

RECRUITING

Henry Ford Cancer Institute, Detroit

63110

RECRUITING

Washington University Medical Campus, St Louis

Unknown

RECRUITING

Grand Hopital de Charleroi (GHdC) - Hopital Notre Dame, Charleroi

RECRUITING

National Institute of Oncology, Chisinau

RECRUITING

Hosp 12 de Octubre, Madrid

RECRUITING

Hospital General Universitario Gergorio Maranon, Madrid

All Listed Sponsors
lead

Sairopa B.V.

INDUSTRY